BUPA Finance PLC
28 September 2026
RNS
LEI Number: ZIMCVQHUFZ8GVHENP290
28 September 2026
THIS ANNOUNCEMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OF SALES WOULD BE PROHIBITED BY APPLICABLE LAW
Publication of Admission Particulars
Bupa Finance plc today announces it has published Admission Particulars dated 25 September 2026 relating to £300,000,000 6.875 per cent. Fixed Rate Subordinated Notes due 2038 (the "Notes"), with Bupa Finance plc as issuer.
To view the full document please paste the following URL into the address bar of the browser http://www.rns-pdf.londonstockexchange.com/rns/6049W_1-2026-9-28.pdf
For further information, please contact:
Investors
Mike Lunn (Group Treasury and Capital Management Director): ir@bupa.com
Media
External Relations: external.relations@bupa.com
About Bupa
Established in 1947, Bupa's purpose is helping people live longer, healthier, happier lives and making a better world. We are an international healthcare company serving 68 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers. Bupa has businesses around the world, principally in Australia, the UK, Spain, Poland, Chile, Hong Kong SAR, India, Türkiye, Brazil, Mexico and New Zealand. We also have associate businesses in Saudi Arabia.
For more information, visit www.bupa.com.
DISCLAIMER - INTENDED ADDRESSEES
This announcement is for information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful.
Please note that the information contained in the Admission Particulars may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Admission Particulars) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Admission Particulars is not addressed. Prior to relying on the information contained in the Admission Particulars you must ascertain from the Admission Particulars whether or not you are part of the intended addressees of the information contained therein.
The Notes have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state of the United States of America and may not be offered or sold to U.S. persons or to persons within the United States of America (as such terms are defined in Regulation S under the Securities Act), except pursuant to an exemption from the Securities Act. For a further description of certain restrictions on offers and sales of the Notes and on distribution of the Admission Particulars, see the "Subscription and Sale" section of the Admission Particulars.
Your right to access this service is conditional upon complying with the above requirement.
END.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.